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ntravitreal administration of dexamethasone (Dex) and triamcinolone (TAA) is commonly used in clinical practice to treat underlying inflammatory changes in a wide range of retinal pathologies, including diabetes, uveitis, and choroidal neovascularization. Despite their established therapeutic benefit, side effects such as cataract formation and ocular hypertension/glaucoma raise concerns. 1 Clinical decision-making could be greatly enhanced with a better appreciation of the differential gene expression induced by intravitreal steroids. In this study we examined the differential gene expression effects of intravitreal injections of Dex and TAA in C57BL/6J mouse neurosensory retinal tissue in vivo, at clinically relevant time points of 1 week and 1 month postinjection. The dosages used in mice were comparable to the doses that are commonly used in intravitreal injections in humans (0.1 mg of Dex in 1 mL of vitreous and 1 mg of TAA in 1 mL of vitreous). Microarray analysis was used to identify common and unique changes in gene expression and activated pathways between the two steroids at two clinically relevant time points. Our findings suggest a delicate balance between protective and deleterious effects of the genes and pathways that might be causing beneficial anti-inflammatory and neuroprotective responses, as well as those that could be causing neuronal damage of the retina as a result of the glial cell inflammatory response.
METHODS

Animals
All research was conducted in compliance with the ARVO Statement for the use of animals in ophthalmic and vision research. We used male C57BL/6J mice (Jax-West, Sacramento, CA) for all experiments. For each time point (1 week and 1 month) we had three groups of animals with four animals per group, 6 to 8 weeks of age.
Mouse Anesthesia
Ketamine (1 mL, 100 mg/mL), 0.1 mL of xylazine (100 mg/mL), and 8.9 mL of sterile water were mixed to prepare a final solution for injection. Animals were anesthetized by injecting 0.1 mL/10 g body weight intraperitoneally.
RNA Isolation
At 1 week and 1 month postinjection, mice from each group were euthanized, using a CO 2 chamber, and the eyes were harvested for retinal tissue using published procedures. 2 Dissected retinas were immediately placed in 300 L RNA stabilization reagent (RNAlater; Qiagen Inc., Valencia, CA) and stored at Ϫ20°C. Retinas were next homogenized using a 1-mL syringe and an 18-gauge needle. An isolation kit (RNeasy; Qiagen) was used to isolate total RNA from the tissue. RNA samples were run on a microfluidics chip-based platform (BioAnalyzer RNA Nano 6000; Agilent Technologies, Santa Clara, CA) to assess quality and quantity. Of the four samples, the three having the highest quality (RNA Integrity Number [RIN] Ն 7 value) were labeled as probes for the microarrays (Affymetrix GeneChip; Affymetrix, Santa Clara, CA).
Microarray Probe Labeling
RNA samples were labeled using 0.100 g of total RNA, following the manufacturer's protocol for small sample (Gene-Chip Two-cycle Target Labeling Assay; Affymetrix). 2 After labeling, probes were hybridized to microarrays (Affymetrix Mouse Genome 430 2.0 GeneChip Array). This array contains 45,101 probe sets, analyzing the expression of 39,000 transcripts and variants from over 34,000 well-characterized mouse genes. Hybridization was performed in the University of California Davis Genome Center Microarray Core Facility using a standard procedure (Affymetrix). The total data set included 18 microarrays (GeneChip; Affymetrix).
Data Normalization
The data sets were analyzed with gene expression analysis software (GeneSpringGX 11; Agilent Technologies), using the robust multiarray analysis (RMA) algorithm. Raw .cel files were imported into the analysis software GeneSpringGX 11 and the RMA summarization algorithm was applied with chip-chip normalization using baseline to median of all samples. Probe sets were filtered to their raw signal intensity values (36,326 of 45,101 passed the filter), with the criterion that 100% of the samples in any one of six conditions must have values between the 20th and 100th percentiles in the data.
Statistical Analysis
One-way ANOVA was used to identify statistically significant genes at a significance level of P Յ 0.01. The Benjamini-Hochberg post hoc correction method was too conservative for microarray results with the limited number of biological replicas such as this. No probe sets met this significance level of testing. Therefore, a different set of stringency requirements was applied to reduce the risk of false positives. To identify biologically relevant gene expression changes for each of the time point/treatment conditions, Volcano plot analysis 3 was performed, using a combination of unpaired t-test and asymptotic P value computation. The Volcano plot is a scatter plot of the foldchange versus the P value (in Ϫlog 10 P scale). It is commonly used to simultaneously depict the P value and the fold-change for gene selection cutoff schemes in microarray data. It may be viewed as a summary of "statistical" significance and "biological" significance over a large number of genes. We used the standard approach of using a P value (P Յ 0.05) as the primary criterion followed by fold change (Ϫ1.5 Ն FC Ն 1.5) as the secondary criterion to select differentially expressed genes. This approach ensures control of false-positive error and preserves the desired biological significance. 4 The data discussed in this publication have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus 5, 6 and are accessible through GEO Series accession number GSE30701 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accϭ GSE30701). (See Supplementary Material, which contains the complete list of the differentially expressed genes identified by ANOVA at P Յ 0.01 and Volcano plot at [Ϫ1.5 Ն FC Ն 1.5], P Յ 0.05; http://www.iovs.org/lookup/ suppl/doi:10.1167/iovs.10-7084/-/DCSupplemental.)
Bioinformatics/Pathways Analysis
Biological pathway analysis was performed using pathway analysis software (Ingenuity Pathway Analysis [IPA]; Ingenuity Systems, Redwood City, CA). The lists of candidate genes identified by statistical analysis were uploaded to pathway analysis software (IPA), and a core analysis algorithm was applied to provide a list of activated pathways and gene networks with the highest degree of significance.
Quantitative PCR
Quantitative PCR (qPCR) was performed as a second method of validation of candidate genes. All gene expression assays (Taqman; Applied Biosystems, Foster City, CA) were conducted in the Realtime PCR Research and Diagnostic Core Facility at University of California Davis.
RESULTS
Genes with Significantly Altered Expression Changes
Statistical analysis by one-way ANOVA identified 1558 probe sets differentially expressed at P Յ 0.01 when the whole 18-chip sample set was considered. One-way ANOVA analysis for each of the time points separately identified 462 genes at 1 week and 597 genes at 1 month that were differentially expressed at P Յ 0.01. Comparison of treatment versus control for each time point using an unpaired t-test identified a set of common genes similarly regulated for both steroids as well as a set of unique genes differentially regulated by each steroid. 
Independent Validation of Data by qPCR
Independent qPCR validation of representative differentially expressed genes was performed using commercial gene expression assays (TaqMan; Applied Biosystems). The fold changes and their direction were confirmed for the chosen sets of genes. Data are presented in Table 7 .
Biological Network and Pathway Analysis of Significantly Changed Genes
Biological network/pathway analysis was performed with pathway analysis software (IPA) to identify integral biological pathways that are commonly and uniquely affected by the two steroids at early and late time points. ANOVA of the whole set identified 1558 probe sets differentially expressed at P Յ 0.01. From this data set the most interesting candidate pathway is "Semaphorin Signaling in Neurons," a member of the "Axonal Guidance Signaling System." The top canonical pathways (identified by IPA) are represented in Table 8 . 
Gene Network Analysis of Significantly Changed Genes
Although pathway analysis shows vertical flow of signaling from the cellular membrane toward the nucleus and DNA, gene network analysis preferentially shows horizontal gene interactions and highlights cross-talk between different gene expression pathways. The top five gene networks for each of the steroids at both time points observed are presented in Table 9 . All steroid/time point combinations have one network in common: "Cell-to-Cell Signaling and Interaction." In Figure 3 , the "Cell-to-Cell Signaling and Interaction Network" is overlaid with information on how its genes/gene complexes feed into some top canonical pathways ("Glucocorticoid Receptor Signaling," "Acute Phase Response Signaling," "Semaphorin Signaling," etc.) and many functional categories (ophthalmic disorders, activation of neuroglia, anti-inflammatory response of macrophages, etc.). To take a closer look at changes in gene expression of the genes making up that network, see Figure 3 . Color coding shows the dynamics of the gene expression changes in each steroid/time point combination: red represents upregulation and green downregulation.
Candidate Genes and Pathways for Retinal Neuroprotection/Neurodegeneration Induced by Steroids
Genes Common for Dex and TAA: 1 Week. Upregulated Ͼ1.5-fold were two genes for stress response proteins: Serpina3n, a murine ortholog of antichymotrypsin, and Cebpd. Moderately upregulated were genes with a role in immune response and apoptosis (Smad3, a member of TGF-␤ receptor signaling and Ripk1, a member of the TNF-␣ signaling cascade), cell adhesion, and retina development in camera-type eye (Pvrl1), as well as somatostatin receptor (Sstr2), a G-protein-coupled receptor for the neuropeptide signaling pathway, and part of the cellular response to glucocorticoid stimulation (Table 1) . Genes Unique for Dex: 1 Week. A common theme was activation of retinal glia macrophages and activation of genes that are regulated by transforming growth factor-␣, nuclear factor-B, and tumor protein p53. Upregulated (fold change: FC Ն 1.5) were genes for several acute-phase proteins (Gfap, Cp, Edn2, Crym, Soc3) and apoptosis-related genes (Bcl3, Nupr1). The top canonical pathways identified by pathway analysis (IPA) were "Glioma Invasiveness Signaling" and "VEGF Signaling Pathway" (Table 8B) . Upregulated were also members of "Semaphorin Signaling in Neurons," Plxna2 and Sema5a. The strongest downregulation was observed with EphrinB receptor (Argef15), a negative regulator of excitatory synapses formation, 7 and several chemokine signaling molecules (Ccl22, Cxcr7, Ccl20) ( Table 2) .
Genes Unique for TAA: 1 Week. Two members of the folate pathway were disregulated: Folh1, a member of "One Carbon Pool by Folate," and Cubn, a gene locus for albuminuria. 8 Also upregulated were genes from the immune and inflammatory response (Glycam1, Calca), dopamine metabolism, and signaling (Cyp2d22, Gnas), as well as a positive regulator of vascular endothelial growth factor (VEGF) (Gata4). Strongly downregulated genes were Kcnj13, a potassium ion channel gene whose mutations cause autosomal-dominant snowflake vitreoretinal degeneration, 9, 10 and Galnt3, a regulator of FGF7 and matrix metalloproteinase expression, 11 whose mutation causes eyelid calcification.
12 Downregulated were several genes involved with DNA repair (Ube2b, Nono, Fancd2, Pohl), regulation of apoptosis (Xiap, CD74, Bcl7c, Syvn1, Lpar1), angiogenesis (Ccbe1), and synaptic transmission (Dlgap1, Fancd2), as well as Plekhg4, a member of the semaphorin signaling pathway. One of the top pathways unique for TAA identified was "VDR/RXR activation".
Genes Common for Dex and TAA: 1 Month. Strongly upregulated were the genes for the aryl-hydrocarbon (AhR) receptor, involved in signal transduction in response to xenobiotic stimulus, stress, regulator of cell cycle and apoptosis, and Znfinger protein of the cerebellum (Zic3). Downregulated were genes involved in nervous system development and regulation of synaptic transmission (L1cam, Casp8, Pacsin1, Nlgn2), as well as amyloid beta (A4) precursor family members (Apbb1 and Aplp2, and Aplp1 in TAA), involved in photoreceptor cell morphogenesis and response to light stimulus, visual learning, and axonal guidance.
Genes Unique for Dex: 1 Month. One of the top upregulated genes is SNAT1, a gene with an abundant expression in Müller cells, and important in glutamine transport in the retina. 13 Several genes with a role in visual perception, photoreceptor, and nervous system development were upregulated (Agtpbp1, Tsc1). Downregulated were Gfap, a marker of glial cell activation; Arid1a, a member of the glucocorticoid signaling pathway; and several genes with a role in neural development, synaptic plasticity, and neurotransmission (Lrrc4c, Ncdn, Gprin1, and Slc6a17). One of the top canonical pathways unique for Dex was "Huntington's Disease Signaling" and "mTOR Signaling." Downregulated was Syntaxin1, a vesicle-mediated transport protein and SNARE protein, also known as a marker for amacrine cells. 14 -16 Genes Unique for TAA: 1 Month. Several genes with a role in visual perception, photoreceptor maintenance, and retinal homeostasis were disregulated at 1 month with TAA. Upregulated were Chrdl1 and Pvrl3, which are involved in retina morphogenesis in camera-type eyes and Bardet-Biedl syndrome 10. Downregulated were genes for neural precursor protein Nedd4, member of "IGF-1, and glucocorticoid receptor signaling"; Lrrc4c, a regulator of axonogenesis; Prox1, which is involved in optic placode formation involved in camera-type eyes; Cobl, involved in neural tube closure; and Rorb, with a role in visual perception and eye photoreceptor cell development. The gap junction protein 1 was upregulated, as well as Vcan, mutations of which have been associated with VCAN-related vitreoretinopathy, which includes Wagner syndrome and erosive vitreoretinopathy. 17 Two of the top canonical signaling pathways identified were "IGF-1 Signaling" and "Glioma Signaling."
DISCUSSION
Although intraocular steroids have a profound anti-inflammatory clinical effect, several complications are common, including cataract formation and steroid-induced glaucoma. 18 -20 The results of our study highlight this clinical dilemma: whereas glucocorticoids alter the expression of a multitude of anti-inflammatory and neuroprotective genes, they also upregulate immune response genes, likely in glial cells, that cause damage to retinal neural tissue. Studies on steroid-induced glaucoma have shown that TAA and Dex induce dose-dependent, differential gene profiles in human trabecular meshwork (TM) cells, revealed by microarray technol- ogy. 18 -21 Today, the TM epithelium is considered to be the target tissue and the myocilin gene, expressed mainly in TM, the top candidate gene for the development of steroid-induced glaucoma, through the proposed mechanism of increased intraocular pressure (IOP). 22 Although an elevated IOP is a significant risk factor for the development of glaucoma, it is important to note that sight-threatening effects of glaucoma are not necessarily coming from increased IOP but from retinal and optic nerve neurodegeneration. There are examples of patients that have normal pressure glaucoma, as well as patients with no retinal damage that have chronically high IOP. [23] [24] [25] Even in a DBA/2J mouse, a model for secondary angle-closure glaucoma, it has been shown that hypertension is not the only causative factor in glaucomatous optic neuropathy. 26 The mechanisms leading to retinal ganglion cell death are not fully understood and, recently, attention has been shifted to the role of autoimmunity in glaucoma pathogenesis. [27] [28] [29] [30] Examples of immune system involvement with glaucoma include increased autoantibodies in glaucoma patients, 31 altered populations of T cells, 32 glial cell activation in the optic nerve and retina, 33 and activation of antigen presentation, seen as increased expression of the major histocompatibility complex class II by lamina cribrosa astrocytes. 34 Recently, complement factor C1q has been implicated in neuronal death in the DBA/2J mouse glaucoma model 35 and has shown increased expression in glaucomatous retina. 36 It has been shown that increased synthesis and deposition of complement factors C1q and C3 within the retina are induced by elevated IOP.
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Candidate Genes and Pathways for Neuroprotection/Neurodegeneration
Upregulation of several acute phase proteins at 1 week postinjection could potentially be quite damaging to the retina. This set of genes includes Serpina3n, a murine ortholog of antichymotrypsin, Gfap, Cebpd, Cp, Edn2, Bcl3, CD44, and Rras. Antichymotrypsin is upregulated during photoreceptor degeneration in the Bbs4-knockout mouse model. 38 It is also induced by inflammatory stimuli in ocular tissue in endotoxin-induced uveitis in rats to prevent degenerative proteolysis, 39 and in the pineal gland as a result of peripheral nerve injury, suggesting its involvement during early events after nerve injury and repair. 40 Photoreceptor-derived endothelin 2 (Edn2) has been reported to be a general stress signaling molecule to Müller cells after photoreceptor injury. 41 Similar findings of activation of acutephase genes were reported by Zhu et al. 42 in their microarray study of differentially induced genes in the inferior and superior retina after hyperoxic shock, suggesting steroid-induced activation of oxidative response genes.
Since one of the common unwelcome side effects of intravitreal steroid administration is glaucoma, we wanted to determine whether any of the differentially expressed genes that we identified are identical or related to the genes identified by microarray analysis of DBA/J mice, a mouse glaucoma model. 43, 44 We found several genes with a common pattern of differential expression in our steroid-injected mice and DBA/2J mice. Steele et al. 43 found upregulation of Lcn2, Gfap, Serpina3n, Edn2, Cp, Olfml3, and downregulation of Selenbp1 at 8 months vs. 3 months in the DBA/2J retinas. In the survey of genes preceding occurrence of increased IOP, Fan et al. 44 identified an increase in Edn2, Lcn2, Gfap, Sst, and GstM1, and decrease in Bcl2, and Camk4 expression. In our data set we see upregulation of Serpina3n after injection of either steroid at 1 week, Edn2, Cp, GstM1, and Gfap in Dex at 1 week, Lcn2 in TAA at 1 week, and upregulation of Selenbp1 TAA at 1 month. So, it remains to be seen whether upregulation of these genes has a protective or damaging effect on retinal and optic nerve degeneration, as well as glaucoma development.
Our results point out a few signaling pathways involved at the clinically relevant time points of 1 week and 1 month postinjection.
Semaphorin Signaling in Retinal Diseases
One of the top pathways identified using pathway analysis of the ANOVA-identified genes at a statistical level (P Յ 0.01) was "Semaphorin Signaling in Neurons." Semaphorins are signaling molecules, secreted and/or membrane bound, that act as axonal growth cone guidance molecules. They are expressed on glial cells, whereas semaphorin receptors, plexins, neuropilins, and integrins are expressed on the neurons. 45 Besides their role in axonal guidance, semaphorins also have a major role in immune function. Figure 2 displays the activation and differential regulation of genes for semaphorins and their receptors from the associated pathway at each steroid/time point. At 1 week after Dex treatment we observed upregulation of genes for ligands Sema3, Sema4, and Sema5a on the glial side, and Plexins A and A2 receptors on the neuronal side. One week after TAA injection we observed upregulation of Sema4 and Sema3, whereas Plexins A and A2 (Plekhg4) were downregulated. At 1 month postinjection Sema4 and Sema3, and plexins are downregulated with Dex, whereas in TAA upregulation of Sema3 is still observed.
Semaphorin 4A is highly expressed in brain and retina, and has an important function in the developing visual system. This is demonstrated in the mouse knockout of Sema4A, which develops severe retinal degeneration. 46 Acting as a cue for neuronal guidance, semaphorin 3A has been found to be secreted by ischemic neurons in the avascular retina in response to the proinflammatory cytokine IL-1␤, thus preventing vascular regeneration in proliferative retinopathies. 47 The role of Sema3E in eye therapy is currently being debated in the literature: both inhibition of semaphorin 3E 48 as well as intravitreal application 49 of semaphorin 3E are proposed strategies for therapeutic anti-angiogenesis. In later work, semaphorin 3E-Plexin D1 signaling has been shown to initiate a signaling pathway that normalizes angiogenic directionality in both developing retinas and ischemic retinopathy. In that work a new paradigm has been suggested for vascular regeneration therapy based on the regulatory interplay of astrocyte-derived VEGF, which normally promotes PlexinD1 expression in growing blood vessels, and neuron-derived semaphorin 3E signals to PlexinD1, which counteract VEGF-induced filopodial projections. Intravitreal administration of semaphorin 3E selectively suppressed extraretinal vascular outgrowth without affecting the desired regeneration of the retinal vasculature. Sema5A, upregulated 1 week after Dex injection, has been shown to promote angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis in vitro. 50 Semaphorin 5A has also been shown to represent a bifunctional axonal guidance cue for mammalian midbrain neurons as well as axial motoneurons in vivo. 51 Activation of the semaphorin 4D-plexinB signaling complex produces an acute collapse of axonal growth cones in retinal neurons.
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Sema7A is expressed by components of the glial scar, such as reactive astrocytes, and in general appears to be a marker for astrocytic activation. 53 However, we do not see any involvement of this semaphorin with our steroid intravitreal injections. We do see activation of a gene for another glial scar protein, glial fibrillary acidic protein (Gfap), which is also a member of the semaphorin pathway. This protein is considered an exclusive marker for Müller cells in the retina and to the retinal injury response. 54 Multiple disorders are associated with improper Gfap regulation leading to "glial scarring." The scar acts as a barrier to neuronal growth and prevents neural regeneration, 55 such as in proliferative vitreoretinopathy in the mouse 56 and Alexander disease. 57 This protein also has a neuroprotective role and increases regeneration of neurons after an injury. 58 Gfap is reported to decrease dramatically in response to acute infection or neurodegeneration. 59 Our data show that Gfap is upregulated by both Dex and TAA at 1 week, and downregulated at week 4. Another member of the semaphorin pathway, gene for X-linked inhibitor of apoptosis, Xiap, has been shown to increase survival of transplanted rod precursors in a degenerating host retina. 60 Xiap is downregulated by steroids at 1 week, and upregulated at the 1 month time point.
Folate Signaling and Retinal Diseases
Folate signaling appears to play a significant role, especially in TAA-injected animals. Folate, a water-soluble vitamin essential for the synthesis of DNA, RNA, and proteins, is required for cell survival. Folate deficiency has deleterious consequences on the retina. Folate deficiencies can precipitate accumulation of homocysteine, which has been implicated in retinal diseases such as maculopathy, open-angle glaucoma, and diabetic retinopathy. 61 One week after TAA injection, folate hydrolase gene (Folh1), a member of the "One Carbon Pool by Folate" pathway was significantly upregulated. The overexpression of Folh1 has been associated with retinal degeneration in Canavan disease. 62 Cubilin (Cubn), another member of the folate pathway and a gene locus for albuminuria, 8 is downregulated with TAA at 1 week time point. 
Somatostatin Receptor Signaling
At 1 week postinjection both Dex and TAA treatments show small, but statistically significant (P Յ 0.01) upregulation of somatostatin receptor 2 gene (Sstr2). Somatostatin is expressed on amacrine cells and serves as a neuromodulator in the CNS and retina. Sstr2 expression has been localized to photoreceptors and rod bipolar cells of the retina, and it has been shown via a mouse Sst2 knockout that somatostatin signaling regulates glutamate release in the retina via somatostatin receptor 2. 63 It has been suggested that Sstr2 has an antiangiogenic role in the retina, 64 and thus its upregulation, in our case, might be a result of the protective effect of steroids against inflammation. mapped to the AhR pathway. 66, 67 Members of the AhR family play critical roles in a broad range of biological functions, including regulation of circadian rhythm, neurogenesis, hypoxia response, and drug metabolism. Aryl-hydrocarbon receptor mediates these effects through interactions with various proteins: retinoblastoma, transforming growth factor-␤, estrogen receptor, and nuclear factor-B. 68, 69 Proteins related to AhR are of particular interest, because there are several currently available drugs that target these molecules. 70 Because neurodegeneration of retinal ganglion cells and retinal tissue in glaucoma leads to vision loss, understanding the molecular and genetic effects of intraocular steroid treatments may be important in reducing clinical complications. Our focus in data interpretation was on genes with known neuroprotective versus neurodegenerative effects and/or known role in ophthalmic or neurodegenerative diseases. We have identified several genes and pathways that appear to be affected by intravitreal steroid injections. Perhaps modulation of some of these potential targets in combination with steroid intravitreal therapy will, in the future, lead to reduced side effects.
Why do different steroids show a difference in subsets of genes that they activate? There are several published whole genome analyses comparing two or three related steroids in TM human cells in vitro showing common and unique sets of genes for each steroid. 18, 20, 21 To our knowledge, this is the first such work done in vivo in mouse retinas. A study on structure-function analysis was recently published by Cidlowski and colleagues 71 that revealed 9-fluoro and 17-hydroxy groups on the steroid significantly impact glucocorticoid receptor (GR) distribution. Since Dex and TAA differ at this position, this might be a partial explanation of those differences. Even a slight conformational difference of the GR, which results from binding of different steroid ligands, such as Dex and TAA, can be multiplied through combinatorial action of steroid receptors with coreceptors and other members of transcriptional machinery, thus having an effect on the level of activation/repression of particular genes, or changing the target genes all together. In addition, Cidlowski 72 has very nicely reviewed the complexity and diversity of the glucocorticoid receptors in human tissue. All that complexity has to be taken into account in any attempt to explain the complex and differential response that we observed for Dex and TAA gene expression in retinal tissue.
Our data show that different glucocorticoid steroids manifest similar yet distinct effects on inflammation, neuroprotection/neurodegeneration, cytokine expression, and oxidative stress pathways that may have important clinical relevance for treatment of specific retinal disorders. These genes and pathways are common to a variety of retinal disorders where intravitreal steroid treatments have been used, including complications from age-related macular degeneration, diabetic retinopathy, venous occlusive disease, and retinal degenerations. A better understanding of the specific targets of steroids and their effects on gene expression in the retina may have important clinical implications for better management of different retinal disorders in the near future.
